MedTrace Logo

Saccharomyces Boulardii as Pretreatment Before Rescue Therapy of Helicobacter Pylori

NCT05191875 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 106

Last updated 2022-05-24

No results posted yet for this study

Summary

The increasing rate of drug resistance in often leads to eradication failure and the need for rescue therapy, and it is of great significance to explore new rescue therapeutic regimens. In this study, we observed the efficacy of rescue treatment of Helicobacter pylori (H.pylori) with Saccharomyces boulardii (S.boulardii) alone. the primary outcome of the trial was the eradication rate, and the secondary outcome was the incidence of adverse events.

Conditions

  • Helicobacter Pylori Infection

Interventions

DRUG

Saccharomyces Boulardii 250 MG

Saccharomyces Boulardii: 0.25 g \* 6, Produced by The French encyclopedia pharmaceutical Factory

DRUG

Ilaprazole.Doxycycline. Furazolidone. Colloidal Bismuth Tartrate

Ilaprazole: 5mg\*6, produced by Livzon Pharmaceutical Group Inc Doxycycline: 0.1 g \* 10, produced by Jiangsu Yongxin Ltd. Furazolidone: 0.1g\*100 produced by Tianjin Lisheng Pharmaceutical Co., LTD Colloidal Bismuth Tartrate: 55 mg \* 36,produced by Shanxi Xinbaoyuan Pharmaceutical Co., LTD

Sponsors & Collaborators

  • The Third Xiangya Hospital of Central South University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-01
Primary Completion
2022-04-12
Completion
2022-04-23

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05191875 on ClinicalTrials.gov